Hutchmed has concluded enrolment of its multi-centre Phase II trial of fanregratinib (HMPL-453), a treatment for intrahepatic ...

However, developing highly selective FGFR2/3 inhibitors and overcoming drug resistance remain two of the most significant challenges in the field. Recently, Insilico Medicine ("Insilico ...

However, developing highly selective FGFR2/3 inhibitors and overcoming drug resistance remain two of the most significant challenges in the field. Recently, Insilico Medicine (“Insilico ...

Genescience Pharmaceuticals Co. Ltd. has prepared and tested new fibroblast growth factor receptor 2 (FGFR2) and/or FGFR3 inhibitors reported to be useful for the treatment of cancer, ...

The firm expects to report topline data from the trial near the end of 2025 and may submit the data as part of a regulatory application in China.

Relay Therapeutics, Inc.’s RLAY share price has dipped by 13.33%, which has investors questioning if this is right time to ...

HUTCHMED has announced the completion of patient enrollment in a Phase II trial for fanregratinib (HMPL-453), aimed at treating intrahepatic cholangiocarcinoma (IHCC) patients with FGFR2 fusion ...

IHCC is a type of primary bile duct cancer, and FGFR2 fusion has been found in 10-15 percent of IHCC patients. HUTCHMED retains global rights to fanregratinib. HCM closed Wednesday's (Mar. 05 ...

Eisai has filed for approval in Japan for tasurgratinib, its small-molecule fibroblast growth factor (FGF) receptor inhibitor, as a treatment for biliary tract cancers with FGFR2 gene fusion ...

Eisai will maintain the rights to tasurgratinib worldwide outside of the licensed regions.

The single-arm, open-label registration study aims to assess the therapy’s safety, pharmacokinetics, and efficacy in advanced IHCC subjects who have FGFR2 fusion/rearrangement. Its primary ...